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sub- locations in Kenya where hundred community health workers were trained 
on community based referral and counter referral model and issued with referral 
tools. Each was assigned 25 households, instructed to regularly visit them in order 
to identify sick persons counsel and refer them to link hospitals. One hundred vil-
lages comprising 2209 households with a population of 11,000 people were covered 
where the counter referral model was implemented. Results: Three hundred and 
twenty two sick persons were identified, counseled and referred to the two link 
health facilities by one hundred community health workers who covered one hun-
dred villages. It was further shown that 82% (263/322) arrived in the referral health 
facilities with referral slips on the same day, 5% (15/322) second day, 6% (20/322) 
third day and over while 7% (24/322) did not arrive in the hospitals. ConClusions: 
It was observed that community health workers regularly visited households. This 
observation is consistent with findings of previous similar studies. Only about less 
than a third of all the referrals did not arrive the link referral hospital the first day. 
It is therefore concluded that community health workers are a critical link between 
the households and primary health care facilities. They are likely to identify com-
mon illnesses during routine household visitation, counsel and refer sick persons 
to health facilities for care.
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objeCtives: A core outcome set (COS) is a standardised set of outcomes which 
should be measured and reported, as a minimum, in all effectiveness trials for a 
specific health area. This will allow results to be compared, contrasted and com-
bined as appropriate, as well as ensuring that all trials contribute usable informa-
tion. The aim of this review was to identify studies which sought to determine 
which outcomes or domains to measure in all clinical trials in a specific condition, 
and to describe the methodological techniques used in these studies. Methods: 
We developed a multi-faceted search strategy for electronic databases (MEDLINE, 
SCOPUS, and Cochrane Methodology Register). We included studies which sought 
to determine which outcomes/domains to measure in all clinical trials in a specific 
condition. Results: 198 studies (250 reports) were included in the review. Studies 
covered various areas of health, most commonly cancer, rheumatology, neurology, 
heart and circulation, and dentistry and oral health. A variety of methods have been 
used to develop COS, including semi-structured discussion, unstructured group 
discussion, the Delphi Technique, Consensus Development Conference, surveys and 
Nominal Group Technique. The most common groups involved were clinical experts 
and non-clinical research experts. Thirty-one (16%) studies reported that the public 
had been involved in the process. The geographic locations of participants were pre-
dominantly North America (n= 164; 83%) and Europe (n= 150; 76%). ConClusions: 
This review has brought together the existing research in a single place. COS will 
increase the efficiency and value of the research process and make it easier for 
people to make well-informed decisions about health care. Design of new trials 
will be simplified, risk of measuring inappropriate outcomes reduced, and selec-
tive reporting of outcomes less likely. We have highlighted future areas of research, 
including the need for methodological guidance for COS development and better 
reporting of COS studies.
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objeCtives: Increasingly, patients are becoming more active contributors to 
research. The purpose of this survey was to understand the experience and expec-
tations of patient organizations (POs) with clinical research and patient reported 
outcomes. Methods: An online survey was conducted in English language during 
May 2014 among 40 participants of a global cross disease patient forum. The infor-
mation was used to provide background regarding patients as active contributors in 
clinical research. The participants represent a broad range of disease specific and 
general patient organizations from various countries including USA, European coun-
tries, Asia, Latina America, Middle East and Australia. Results: The most important 
deficiencies of current clinical research practice were described as a lack of patient 
friendly reporting, incomplete reporting and a lack of patient involvement in the 
study design. Over the half of respondents stated that clinical trials are conducted 
in a way that does not yield information relevant to the patients. Active involvement 
in clinical trials was specified through 79 different expectations which fell into 7 
categories: (1) Accessibility of new medicines (2) More representative patient selec-
tion for studies (3) Transparent conduct of the study (4) Better information on safety 
and risks to participants (5) Active versus passive role of patients (6) Contribution 
to innovation (7) Improved result reporting; especially to patients. One third of the 
respondents have already been actively involved in clinical research and felt that this 
was a mostly positive experience. Globally, patients and patient organizations are 
becoming increasingly involved in clinical research through multiple formal or infor-
mal routes of engagement. ConClusions: Patients should be better represented in 
clinical research and consulted for patient relevant study aspects in order to provide 
information of greater relevance to patients in their own therapeutic decisions.
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objeCtives: Traditionally, drug repurposing has been considered as a cost-effective 
and a reduced-risk strategy for developing new drugs. Currently little is known and 
documented regarding efficiency of repositioning strategies in drug development. 
The objective of this article is to assess the meaning of this process with focus on 
CNS area. We aim to identify the repositioning strategies that conducted to the 
discovery and development of new CNS products as well as identify the source and 
target indication and development status. Methods: In order to identify repur-
posing cases that target CNS, an extensive research was performed. It included a 
literature review as well as search of websites of organizations engaged in promot-
ing and development of drug repurposing. Cases were extracted from the source 
material. For each molecule, its initial and target indication as well as development 
status was recorded. Each case was classified by type of repurposing strategy (repo-
sitioning, reformulation or both). Results: 109 source products were identified. 
They were repositioned 183 times. About one third of the source products have 
been repositioned more than one time. Half of new indications was approved. The 
majority of cases were repositioned while only 10 were reformulated and 16 were 
reformulated and repositioned at the same time. The highest number of repurposed 
molecules was originating from CNS therapeutic area (67 molecules targeted 127 
indications). Among new therapeutic indications alcohol / opioid / drug dependence 
was targeted most often (20 repositions). Regarding repositions within CNS area, 
Schizophrenia, Epilepsy and Depression were the richest sources of repositioned 
drugs with 10 and more products each. ConClusions: Drug repurposing in CNS is 
an efficient and currently very active drug development strategy, exemplified by the 
considerable amount of new indications that have been found via this strategy, with 
approximately half of the target indications being currently under development.
PHP185
ComPonents oF sustainaBle HealtH systems: wHat is known aBout 
tHe Cost-eFFeCtiveness oF CliniCal Care?
Tordrup D., Stephan L., Bertollini R.
World Health Organization, Bruxelles, Belgium
objeCtives: Evidence to ensure cost-effective purchasing of services are an 
important pre-requisite for ensuring financial sustainability of health systems. 
The Research Agenda for Health Economic Evaluation project aims to map out the 
economic evidence available for the treatment of the 10 highest burden conditions 
in the European Union and identify evidence gaps. Methods:  The 10 highest 
burden diseases are selected by Disability Adjusted Life Years (DALYs) based on 
the Global Burden of Disease study for Europe (Ischemic Heart Disease, Low Back 
Pain, Stroke, Major Depressive Disorder, Lung Cancer, Falls, COPD, Diabetes, Other 
musculoskeletal, Neck pain). Clinical pathways are generated for these conditions by 
merging published clinical guidelines from public and professional bodies. Economic 
(cost-benefit and cost-effectiveness) evidence indexed by MEDLINE is stratified by 
treatment pathways to identify evidence gaps. Existing reviews are analysed to 
assess coverage of primary evidence. Results: Results are presented for diabetes: 
1,208 articles were retrieved from MEDLINE, of which 315 mapped to the treatment 
pathway. Most evidence was published after 2000. 74 reviews were identified, of 
which 24 were published between 2009-13. Volume of economic studies for each 
treatment ranged from 0 to 39 studies. The most intensively studied were diabetic 
retinopathy (n= 39), foot ulcers (n= 34) and renal disease (n= 31). Areas with no eco-
nomic evidence included non-pharmacological blood pressure and dyslipidemia 
control. In some cases economic evidence was available, but no recent reviews of 
the evidence were identified (eg. islet or pancreas transplantation, diabetic neu-
ropathy, interventions for weight loss). ConClusions: Economic evidence was 
available for the majority of treatment modalities for diabetes, however for several 
treatments no studies were identified. Importantly, reviews were not identified 
for several treatments where economic evidence was available. Lack of economic 
evidence prevents cost-effective commissioning, and lack of reviews of evidence 
may be a further barrier to translation.
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objeCtives: China and the United States have approved massive health care 
reforms seeking to increase access to affordable health care services. Both coun-
tries employed a composite of government programs and private enterprises 
designed to improve efficiencies in their health care markets. This study com-
pares the results of these health care reforms so far, explores the longer-term 
prognoses and considers how lessons learnt can inform health care reform else-
where. Methods: In the U.S., 80 MCOs and 240 physicians were surveyed about 
their participation in reform programs. Quarterly data on the uninsured and health 
care cost trend data were also assessed. In China, 670 patients were surveyed 
regarding their access to a health care provider. Results: Early returns show 
mixed results that stem from policy decisions inherent in the original programs 
as well as from national political considerations. Overall, both the U.S. and China 
health care reforms are enjoying success but have shortcomings. In the U.S, parti-
sanship, technology issues, and implementation uncertainties have undermined 
the reform legislation. However, the nation’s uninsured rate declined from 17.1% 
in Q4 2013 to 13.4% in Q2 2014, and the health care cost trend has fallen. Moreover, 
the predicted spike in emergency room utilization has not yet appeared. In China, 
the percentage of citizens with coverage increased from 30% in 2003 to 95% in 2011, 
while patients’ share of out-of-pocket costs fell. However, improvement is felt less 
in rural regions and demand for services is increasing. Consequently, Chinese 
citizens still have difficulty accessing health care providers, which, combined 
with inadequate reimbursement rates, means health care in China remains sub-
optimal. ConClusions: Together with early coverage statistics, responses from 
both the U. S. and China to challenges in their respective health care reform efforts 
indicate that long-term success is achievable. Their experiences underscore the 
